About this FactMed analysis covering adverse side effect reports of ALMARL patients who developed PNEUMONIA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 10 individuals taking ALMARL reported PNEUMONIA to the FDA. A total of 227 ALMARL drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between ALMARL and PNEUMONIA. In doing so, we compare ALMARL with other drugs that cause PNEUMONIA, to help you evaluate whether or not ALMARL causes PNEUMONIA. Likewise, this page shows the most highly-reported side effects of ALMARL, so you can see if PNEUMONIA ranks among ALMARL's most well-known side effects.
Summary Statistics
Reports of ALMARL causing PNEUMONIA: 10
Reports of any side effect of ALMARL : 227
Percentage of ALMARL patients where PNEUMONIA is a reported side effect: 4.4053%

FDA reports of any drug causing PNEUMONIA : 82141
Average percentage for all medicated patients where PNEUMONIA is reported as a complication: 0.5148%

Physician opinion on ALMARL as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing ALMARL:
HYPERTENSION ( 76 patients )
PARKINSON'S DISEASE ( 8 patients )
ESSENTIAL TREMOR ( 6 patients )
ATRIAL FIBRILLATION ( 4 patients )
SCHIZOPHRENIA ( 2 patients )
TREMOR ( 2 patients )
ANGINA PECTORIS ( 2 patients )
DRUG USE FOR UNKNOWN INDICATION ( 2 patients )
PALPITATIONS ( 2 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 2 patients )
TACHYCARDIA ( 2 patients )
HYPERTROPHY ( 1 patients )
( 0 patients )
Drugs with high FDA adverse event association with PNEUMONIA:

ASPIRIN (6898 patients)
FOSAMAX (5009 patients)
PREDNISONE (4778 patients)
REMICADE (4394 patients)
LASIX (4370 patients)
METHOTREXATE (4357 patients)
REVLIMID (4246 patients)
AVONEX (4193 patients)
HUMIRA (4133 patients)
VIOXX (3996 patients)
PREDNISOLONE (3820 patients)
HEPARIN SODIUM INJECTION (3232 patients)
FOLIC ACID (3005 patients)
FUROSEMIDE (2976 patients)
FORTEO (2972 patients)
DEXAMETHASONE (2962 patients)
ZOMETA (2933 patients)
NEXIUM (2845 patients)
OMEPRAZOLE (2722 patients)
COUMADIN (2681 patients)
ENBREL (2641 patients)
ALBUTEROL (2605 patients)
LIPITOR (2588 patients)
LISINOPRIL (2478 patients)
SPIRIVA (2420 patients)
SEROQUEL (2404 patients)
ADVAIR DISKUS 100/50 (2339 patients)
ACETAMINOPHEN (2204 patients)
PROTONIX (2065 patients)
TYSABRI (2047 patients)
PREDNISONE TAB (2030 patients)
DIGOXIN (2009 patients)
POTASSIUM CHLORIDE (1995 patients)
PLAVIX (1969 patients)
SIMVASTATIN (1965 patients)
NORVASC (1927 patients)
SYNTHROID (1904 patients)
NEURONTIN (1893 patients)
CYCLOPHOSPHAMIDE (1880 patients)
ALLOPURINOL (1857 patients)
OXYCONTIN (1821 patients)
DIANEAL (1761 patients)
PRILOSEC (1691 patients)
ZOLOFT (1621 patients)
DECADRON (1608 patients)
EXJADE (1607 patients)
AREDIA (1599 patients)
HYDROCHLOROTHIAZIDE (1597 patients)
VELCADE (1572 patients)
AMBIEN (1542 patients)
ATENOLOL (1521 patients)
LEVOTHYROXINE SODIUM (1517 patients)
LEVAQUIN (1502 patients)
XANAX (1492 patients)
LETAIRIS (1467 patients)
WARFARIN SODIUM (1456 patients)
LORAZEPAM (1437 patients)
VITAMIN D (1431 patients)
LANTUS (1415 patients)
ATIVAN (1387 patients)
CELEBREX (1365 patients)
ZOCOR (1340 patients)
LYRICA (1340 patients)
CISPLATIN (1335 patients)
MORPHINE (1334 patients)
SINGULAIR (1318 patients)
ZOFRAN (1299 patients)
GABAPENTIN (1296 patients)
METFORMIN HCL (1270 patients)
TOPROL-XL (1268 patients)
TRACLEER (1266 patients)
VICODIN (1265 patients)
AMLODIPINE (1264 patients)
DIOVAN (1259 patients)
PERCOCET (1244 patients)
OXYCODONE HCL (1233 patients)
GOLIMUMAB (1230 patients)
REBIF (1196 patients)
INSULIN (1194 patients)
METOPROLOL TARTRATE (1191 patients)
CARBOPLATIN (1159 patients)
CLOZARIL (1154 patients)
CALCIUM (1146 patients)
PREVACID (1138 patients)
DURAGESIC-100 (1108 patients)
ACYCLOVIR (1086 patients)
SYMBICORT (1084 patients)
IBUPROFEN (1083 patients)
PAXIL (1049 patients)
ZYPREXA (1042 patients)
LANSOPRAZOLE (1017 patients)
CYMBALTA (1006 patients)
RITUXIMAB (1006 patients)
RISPERDAL (1000 patients)
MYCOPHENOLATE MOFETIL (991 patients)
LEXAPRO (987 patients)
MULTI-VITAMINS (987 patients)
VANCOMYCIN (971 patients)
CLONAZEPAM (969 patients)
COMBIVENT (965 patients)
FLUCONAZOLE (942 patients)
MULTI-VITAMIN (936 patients)
FAMOTIDINE (931 patients)
COREG (926 patients)
VINCRISTINE (906 patients)
CYCLOSPORINE (905 patients)
LORTAB (900 patients)
FENTANYL (899 patients)
SPIRONOLACTONE (894 patients)
CRESTOR (890 patients)
COLACE (889 patients)
FLUOROURACIL (885 patients)
THALOMID (883 patients)
LOVENOX (873 patients)
ZANTAC (870 patients)
OXYGEN (864 patients)
NITROGLYCERIN (854 patients)
THALIDOMIDE (845 patients)
HEPARIN (835 patients)
ALPRAZOLAM (833 patients)
CIPROFLOXACIN (833 patients)
XOLAIR (821 patients)
MAGNESIUM OXIDE (821 patients)
VITAMIN B-12 (813 patients)
LEVOFLOXACIN (803 patients)
CALCIUM CARBONATE (790 patients)
NEUPOGEN (788 patients)
TRAMADOL HCL (787 patients)
FLOMAX (786 patients)
AMOXICILLIN (781 patients)
CLOZAPINE (775 patients)
MORPHINE SULFATE (774 patients)
ATROVENT (772 patients)
COMPAZINE (766 patients)
PREMARIN (765 patients)
ZITHROMAX (757 patients)
METOPROLOL (755 patients)
DIFLUCAN (752 patients)
DIAZEPAM (747 patients)
CYTARABINE (745 patients)
CELEXA (745 patients)
TACROLIMUS (743 patients)
PANTOPRAZOLE (743 patients)
DOXORUBICIN HCL (741 patients)
REGLAN (736 patients)
ALENDRONATE SODIUM (735 patients)
VIDAZA (734 patients)
BACLOFEN (733 patients)
DILAUDID (724 patients)
CARVEDILOL (721 patients)
ETOPOSIDE (721 patients)
COZAAR (719 patients)
LOPRESSOR (718 patients)
ALDACTONE (714 patients)
METHYLPREDNISOLONE (713 patients)
RANITIDINE (712 patients)
RAMIPRIL (712 patients)
ARANESP (704 patients)
FERROUS SULFATE TAB (704 patients)
ASCORBIC ACID (703 patients)
ENALAPRIL MALEATE (701 patients)
EFFEXOR (694 patients)
BACTRIM (692 patients)
PROZAC (689 patients)
TYLENOL (CAPLET) (688 patients)
RIBAVIRIN (686 patients)
AVANDIA (685 patients)
VENTOLIN (679 patients)
TAXOTERE (677 patients)
PROGRAF (675 patients)
GLEEVEC (668 patients)
TOCILIZUMAB (665 patients)
HUMALOG (660 patients)
PEPCID (658 patients)
NYSTATIN (654 patients)
SANDOSTATIN LAR (651 patients)
DOCETAXEL (648 patients)
AVELOX (647 patients)
TRAZODONE HCL (646 patients)
NEORAL (642 patients)
KLONOPIN (642 patients)
PREDONINE (634 patients)
AMITRIPTYLINE HCL (629 patients)
ZYRTEC (628 patients)
TYLENOL (627 patients)
LACTULOSE (615 patients)
FLEXERIL (615 patients)
BYETTA (612 patients)
AMIODARONE HCL (611 patients)
PACLITAXEL (610 patients)
ONDANSETRON (609 patients)
AZITHROMYCIN (605 patients)
SOLU-MEDROL (605 patients)
GLUCOPHAGE (603 patients)
WELLBUTRIN (603 patients)
AVASTIN (597 patients)
KLOR-CON (596 patients)
GLYBURIDE (595 patients)
MS CONTIN (590 patients)
SYNAGIS (590 patients)
BENADRYL (590 patients)
FLONASE (587 patients)
DEXAMETHASONE TAB (582 patients)
VALIUM (582 patients)
ACTOS (576 patients)
RHEUMATREX (575 patients)
AUGMENTIN '125' (573 patients)
FLOVENT (572 patients)
GLIPIZIDE (571 patients)
TAXOL (564 patients)
Most common side effects for patients taking ALMARL:
DEPRESSED LEVEL OF CONSCIOUSNESS (20 patients)
HALLUCINATION (15 patients)
FALL (13 patients)
HYPOGLYCAEMIA (13 patients)
PYREXIA (12 patients)
TREMOR (12 patients)
DIARRHOEA (11 patients)
HEPATIC FUNCTION ABNORMAL (11 patients)
PNEUMONIA (10 patients)
DYSARTHRIA (10 patients)
BLOOD CREATINE PHOSPHOKINASE INCREASED (9 patients)
RENAL FAILURE ACUTE (9 patients)
LIVER DISORDER (9 patients)
CEREBRAL INFARCTION (8 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (8 patients)
DRUG INEFFECTIVE (8 patients)
RENAL IMPAIRMENT (8 patients)
HYPONATRAEMIA (8 patients)
INTERSTITIAL LUNG DISEASE (8 patients)
JAUNDICE (8 patients)
OEDEMA PERIPHERAL (8 patients)
CONDITION AGGRAVATED (7 patients)
DELIRIUM (7 patients)
DYSPHAGIA (7 patients)
DYSPNOEA (7 patients)
HYPOAESTHESIA (7 patients)
RHABDOMYOLYSIS (7 patients)
VOMITING (6 patients)
DELUSION (6 patients)
RESPIRATORY FAILURE (6 patients)
DYSKINESIA (6 patients)
SOMNOLENCE (6 patients)
HEPATIC NEOPLASM MALIGNANT (6 patients)
HYPERGLYCAEMIA (6 patients)
HYPOKALAEMIA (6 patients)
MOVEMENT DISORDER (6 patients)
MUSCULAR WEAKNESS (6 patients)
WHITE BLOOD CELL COUNT INCREASED (5 patients)
BLADDER CANCER (5 patients)
BLOOD ANTIDIURETIC HORMONE INCREASED (5 patients)
RESTLESSNESS (5 patients)
BLOOD OSMOLARITY DECREASED (5 patients)
PLEURAL EFFUSION (5 patients)
C-REACTIVE PROTEIN INCREASED (5 patients)
CONVULSION (5 patients)
RENAL DISORDER (5 patients)
VITH NERVE PARALYSIS (5 patients)
INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION (5 patients)
INTESTINAL OBSTRUCTION (5 patients)
SEPSIS (5 patients)
ROAD TRAFFIC ACCIDENT (5 patients)
MUSCULOSKELETAL PAIN (5 patients)
NAUSEA (5 patients)
ANOREXIA (4 patients)
ATELECTASIS (4 patients)
ATRIAL FIBRILLATION (4 patients)
ATRIOVENTRICULAR BLOCK (4 patients)
BLOOD CREATININE INCREASED (4 patients)
BRADYCARDIA (4 patients)
CARDIAC FAILURE (4 patients)
CONSTIPATION (4 patients)
DECREASED APPETITE (4 patients)
DEHYDRATION (4 patients)
DIZZINESS (4 patients)
PLATELET COUNT DECREASED (4 patients)
PAIN (4 patients)
HYPERTENSION (4 patients)
HYPOTHYROIDISM (4 patients)
ILEUS (4 patients)
METABOLIC ACIDOSIS (4 patients)
SMALL INTESTINE CARCINOMA (4 patients)
URINE OSMOLARITY INCREASED (4 patients)
ABASIA (3 patients)
AGGRESSION (3 patients)
PRURITUS (3 patients)
ANAEMIA (3 patients)
PULMONARY ALVEOLAR HAEMORRHAGE (3 patients)
WHITE BLOOD CELL COUNT DECREASED (3 patients)
ASTHMA (3 patients)
BLOOD BILIRUBIN INCREASED (3 patients)
RENAL FAILURE (3 patients)
BLOOD PRESSURE DECREASED (3 patients)
BLOOD PRESSURE INCREASED (3 patients)
VASCULITIS (3 patients)
CAROTID ARTERY STENOSIS (3 patients)
THERAPEUTIC AGENT TOXICITY (3 patients)
CHILLS (3 patients)
CHROMATURIA (3 patients)
PETECHIAE (3 patients)
CHRONIC LYMPHOCYTIC LEUKAEMIA (3 patients)
PORIOMANIA (3 patients)
RENAL ARTERY STENOSIS (3 patients)
PANCYTOPENIA (3 patients)
DRUG ERUPTION (3 patients)
SUDDEN ONSET OF SLEEP (3 patients)
DRUG WITHDRAWAL SYNDROME (3 patients)
VERTIGO (3 patients)
EPILEPSY (3 patients)
FACE OEDEMA (3 patients)
VOLVULUS (3 patients)
GENERALISED OEDEMA (3 patients)
GINGIVAL BLEEDING (3 patients)
HAEMORRHAGE SUBCUTANEOUS (3 patients)
HALLUCINATION, VISUAL (3 patients)
PSYCHIATRIC SYMPTOM (3 patients)
HEART RATE DECREASED (3 patients)
HELICOBACTER TEST POSITIVE (3 patients)
HEPATITIS FULMINANT (3 patients)
HYPERKALAEMIA (3 patients)
HYPOTENSION (3 patients)
IDIOPATHIC THROMBOCYTOPENIC PURPURA (3 patients)
LOSS OF CONSCIOUSNESS (3 patients)
SENSORY DISTURBANCE (3 patients)
LYMPHOMA (3 patients)
MALAISE (3 patients)
MARKEDLY REDUCED DIETARY INTAKE (3 patients)
RENAL TUBULAR DISORDER (3 patients)
NEOPLASM MALIGNANT (3 patients)
SINUS ARREST (3 patients)
ABDOMINAL DISCOMFORT (2 patients)
ABDOMINAL PAIN (2 patients)
ACUTE MYELOID LEUKAEMIA (2 patients)
STOMACH MASS (2 patients)
PERSONALITY CHANGE (2 patients)
AGITATION (2 patients)
ALTERED STATE OF CONSCIOUSNESS (2 patients)
ANAPHYLACTOID REACTION (2 patients)
ANGER (2 patients)
PRODUCTIVE COUGH (2 patients)
RENAL CYST (2 patients)
APHASIA (2 patients)
ASTHENIA (2 patients)
ATRIOVENTRICULAR BLOCK COMPLETE (2 patients)
THIRST (2 patients)
PROSTATE CANCER (2 patients)
BLOOD AMYLASE INCREASED (2 patients)
BLOOD UREA INCREASED (2 patients)
BODY TEMPERATURE INCREASED (2 patients)
SPEECH DISORDER (2 patients)
TUMOUR LYSIS SYNDROME (2 patients)
CEREBRAL HAEMORRHAGE (2 patients)
CHEST X-RAY ABNORMAL (2 patients)
COLON CANCER (2 patients)
COMA HEPATIC (2 patients)
COMPLETED SUICIDE (2 patients)
CONTUSION (2 patients)
PERFORMANCE STATUS DECREASED (2 patients)
DEFAECATION URGENCY (2 patients)
DEMENTIA ALZHEIMER'S TYPE (2 patients)
RASH PRURITIC (2 patients)
DIABETIC KETOACIDOSIS (2 patients)
DRUG INTERACTION (2 patients)
DRUG LEVEL INCREASED (2 patients)
DYSPEPSIA (2 patients)
DYSSTASIA (2 patients)
ELECTROCARDIOGRAM QT PROLONGED (2 patients)
STEVENS-JOHNSON SYNDROME (2 patients)
EPULIS (2 patients)
EXTRAOCULAR MUSCLE PARESIS (2 patients)
FACIAL PARESIS (2 patients)
FEAR (2 patients)
FEBRILE NEUTROPENIA (2 patients)
FEMORAL NECK FRACTURE (2 patients)
FOOT FRACTURE (2 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (2 patients)
GANGRENE (2 patients)
GASTRIC ULCER HAEMORRHAGE (2 patients)
GINGIVAL HYPERTROPHY (2 patients)
GLOSSOPTOSIS (2 patients)
PLEURISY (2 patients)
PHRENIC NERVE PARALYSIS (2 patients)
HAEMATEMESIS (2 patients)
HAEMATURIA (2 patients)
HAEMOGLOBIN DECREASED (2 patients)
POLLAKIURIA (2 patients)
ORAL INTAKE REDUCED (2 patients)
HEPATIC CYST (2 patients)
HEPATIC ENCEPHALOPATHY (2 patients)
HEPATITIS (2 patients)
HYPERREFLEXIA (2 patients)
HYPERTONIA (2 patients)
HYPERURICAEMIA (2 patients)
RASH PAPULAR (2 patients)
INITIAL INSOMNIA (2 patients)
RETINAL OEDEMA (2 patients)
INTESTINAL FUNCTIONAL DISORDER (2 patients)
RESPIRATION ABNORMAL (2 patients)
IRRITABILITY (2 patients)
RIB FRACTURE (2 patients)
LEG AMPUTATION (2 patients)
LYMPHADENOPATHY (2 patients)
METABOLIC ALKALOSIS (2 patients)
ORAL HERPES (2 patients)
TAKAYASU'S ARTERITIS (2 patients)
MOUTH HAEMORRHAGE (2 patients)
UNRESPONSIVE TO STIMULI (2 patients)
TOXIC SKIN ERUPTION (2 patients)
NEPHROLITHIASIS (2 patients)
SUICIDE ATTEMPT (2 patients)
VENTRICULAR FIBRILLATION (2 patients)
NEUTROPHIL COUNT DECREASED (2 patients)
UPPER RESPIRATORY TRACT INFECTION (2 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (2 patients)
SHOCK HAEMORRHAGIC (2 patients)
ABDOMEN CRUSHING (1 patients)
CARDIAC FAILURE CONGESTIVE (1 patients)
EOSINOPHILIC PNEUMONIA ACUTE (1 patients)
ESSENTIAL TREMOR (1 patients)
WRONG TECHNIQUE IN DRUG USAGE PROCESS (1 patients)
FUNGAL INFECTION (1 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for ALMARL


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about PNEUMONIA and ALMARL, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking ALMARL, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in ALMARL. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for ALMARL experts. If you are a healthcare provider experienced in prescribing ALMARL, please register here.

Your online appointment book for Jenison Rentals & Services

© 2014 FactMed, Inc
Privacy Policy
Terms of Use